Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
15.5 USD +2.31% Intraday chart for Novavax, Inc. +19.14% +222.92%
May. 24 Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
May. 23 Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 93.33 4,079 10,817 883.9 570.2 2,127 - -
Enterprise Value (EV) 1 335.1 3,836 9,756 -228.1 169.7 1,290 1,423 2,127
P/E ratio -0.72 x -15.3 x -6.1 x -1.22 x -0.89 x 35.9 x -35.7 x 36.4 x
Yield - - - - - - - -
Capitalization / Revenue 5 x 8.58 x 9.44 x 0.45 x 0.58 x 2.16 x 3.85 x 4 x
EV / Revenue 18 x 8.07 x 8.51 x -0.12 x 0.17 x 1.31 x 2.58 x 4 x
EV / EBITDA - - - 0.37 x -0.32 x 5.7 x -4.16 x -
EV / FCF -2.42 x -39.5 x 36.8 x 0.45 x -0.22 x 4.47 x -2.05 x 50.7 x
FCF Yield -41.3% -2.53% 2.72% 221% -452% 22.4% -48.7% 1.97%
Price to Book -0.69 x 12.6 x -30.9 x -1.38 x -0.93 x -1.99 x -2.09 x -
Nbr of stocks (in thousands) 23,449 36,578 75,608 85,979 118,790 140,418 - -
Reference price 2 3.980 111.5 143.1 10.28 4.800 15.15 15.15 15.15
Announcement Date 3/11/20 3/1/21 2/28/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 18.66 475.6 1,146 1,982 983.7 986.6 552.3 532.4
EBITDA 1 - - - -615.7 -525.3 226.2 -342.4 -
EBIT 1 -129.6 -416.7 -1,687 -644.7 -566.5 124.2 -27.3 81.37
Operating Margin -694.44% -87.62% -147.13% -32.53% -57.59% 12.59% -4.94% 15.28%
Earnings before Tax (EBT) 1 -132.7 -418.3 -1,715 -653.6 -543 46.03 -41.33 78.23
Net income 1 -132.7 -418.3 -1,744 -657.9 -545.1 68.09 -98.46 63.6
Net margin -711.04% -87.94% -152.12% -33.2% -55.41% 6.9% -17.83% 11.95%
EPS 2 -5.510 -7.270 -23.44 -8.420 -5.410 0.4219 -0.4248 0.4167
Free Cash Flow 1 -138.5 -97.16 265.5 -505 -767.7 288.5 -693.5 42
FCF margin -742.04% -20.43% 23.16% -25.48% -78.05% 29.24% -125.57% 7.89%
FCF Conversion (EBITDA) - - - - - 127.53% - -
FCF Conversion (Net income) - - - - - 423.68% - 66.04%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/11/20 3/1/21 2/28/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 222.2 704 185.9 734.6 357.4 80.95 424.4 187 291.3 93.86 347.8 61.9 480.2
EBITDA - - - -118.8 - - - - -172.8 - - - -
EBIT 1 -825 209.3 -483 -127.2 -243.9 -312.8 55.46 -125.6 -183.6 -144.8 315.3 -142.2 87.93
Operating Margin -371.27% 29.73% -259.76% -17.31% -68.24% -386.37% 13.07% -67.19% -63.01% -154.31% 90.65% -229.67% 18.31%
Earnings before Tax (EBT) 1 -829.7 206.1 -509.1 -166.1 -184.5 -292.7 57.86 -131.5 -176.7 -145.3 148.6 -124.7 155.7
Net income 1 -846.3 203.4 -510.5 -168.6 -182.2 -293.9 58.01 -130.8 -178.4 -147.6 148.4 -124.7 149.1
Net margin -380.87% 28.89% -274.57% -22.95% -50.99% -363.07% 13.67% -69.94% -61.23% -157.21% 42.68% -201.52% 31.04%
EPS 2 -11.18 2.560 -6.530 -2.150 -2.280 -3.410 0.5800 -1.260 -1.440 -1.050 0.9821 -0.8521 0.9382
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/28/22 5/9/22 8/8/22 11/8/22 2/28/23 5/9/23 8/8/23 11/9/23 2/28/24 5/10/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 242 - - - - - - -
Net Cash position 1 - 243 1,061 1,112 400 837 704 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -138 -97.2 265 -505 -768 289 -694 42
ROE (net income / shareholders' equity) - -190% -1,266% - - - - -
ROA (Net income/ Total Assets) -74.4% -47.7% -83.8% -27.2% -26.9% -9.5% -22.3% -
Assets 1 178.3 877.7 2,080 2,418 2,028 -716.8 441.9 -
Book Value Per Share 2 -5.750 8.840 -4.640 -7.440 -5.140 -7.630 -7.240 -
Cash Flow per Share 2 - - - -5.320 -7.090 -1.170 -1.360 -
Capex 1 1.86 220 57.5 89.1 53.8 15.9 5.75 6.1
Capex / Sales 9.95% 46.29% 5.01% 4.49% 5.47% 1.61% 1.04% 1.15%
Announcement Date 3/11/20 3/1/21 2/28/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.5 USD
Average target price
21.6 USD
Spread / Average Target
+39.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVAVAX, INC. Stock Novavax, Inc.
+222.92% 2.13B
MODERNA, INC. Stock Moderna, Inc.
+67.53% 62.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.38B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.64B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.46B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.67B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. Financials Novavax, Inc.